Human Papillomavirus (HPV)

Human papillomavirus causes many diseases especially in the reproductive systems or head and neck area, ranging from genital warts to cancer of the cervix, anus, mouth and penis.


Among many HPV-induced diseases, NeoImmuneTech is primarily aiming at treating HPV persistent infection, for which there is no standard of care. Although there are approved prophylactic HPV vaccines, they cannot treat established chronic infections, nor can they prevent progression to severer conditions such as precancer or cancer. Intravaginal formulation of NT-I7 highly enhances the expansion and function of T cells in chronic cervical HPV infection, and has efficient mucosal delivery by FcRn-mediated transcytosis mechanism in animal experiments, and co-delivery of HPV DNA vaccine (GX-188E of Genexine, Inc.) and NT-I7 substantially enhances the vaccine induced CD8 T cell response, CD8 T cell-mediated anti-tumor effect and survival rate in mice. (YW Choi et. al., Clin Cancer Res. 2016 Dec 1;22(23):5898-5908)

THE PRN NOTEBOOK vol.13, Sep. 2008; BMC Infectious Diseases 2009, 9:119
Summary Report Update on Human Papilloma Virus and Related Cancers, WHO/ICO HPV information Centre, 2010
JNCI J Natl Cancer Inst-2008-Rodr-uez-513